Clinical Trial

A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid tumors harboring KRAS mutations or amplification. The study consists of 2 phases: Phase 1 Dose Escalation and Phase IIa Dose Expansion.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-28.
Trial Details
NCT Number NCT06959615
Lead Sponsor Jacobio Pharmaceuticals Co., Ltd.
Conditions Advanced Solid Tumor
Enrollment 334 participants
Start Date 2024-11-22
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-20